Cat. No. | Product name | CAS No. |
DC7317 |
TG101209
Featured
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations; TG101209 inhibit BRD4 activity with IC50 of 130 nM. |
936091-14-4 |
DC7318 |
TG101348(Fedratinib)
Featured
TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3, TG-101348 also inhibit BRD4 with IC50 of 340 nM. |
936091-26-8 |
DC8511 |
TG-46
Featured
TG-46 is an inhibitor of JAK2, FLT3, RET, JAK3 with IC50 values of 6nM, 25nM, 17nM, 169nM respectively. |
936091-15-5 |
DC8510 |
TG-89
Featured
TG-89 is a JAK inhibitor. It has IC50 values of 6, 25, 17 and 169 nM against JAK2, FLT3, RET and JAK3 respectively. |
936091-56-4 |
DC8736 |
Tofacitinib
Featured
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
477600-75-2 |
DC5165 |
Tofacitinib (CP-690550) Citrate
Featured
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
540737-29-9 |
DC10031 |
TP-3654
Featured
TP-3654 is a small molecule pan-Pim (PIM) kinase inhibitor. |
1361951-15-6 |
DC10431 |
Upadacitinib
Featured
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. |
1310726-60-3 |
DC7581 |
WHI-P154
Featured
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation. |
211555-04-3 |
DC8080 |
WHI-P258
Featured
WHI-P258 is a negative control for JAK3 inhibitors. |
21561-09-1 |
DC9494 |
WHI-P97
Featured
WHI-P97 is a rationally designed potent inhibitor of JAK-3. |
211555-05-4 |
DC5022 |
XL019
Featured
XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. |
945755-56-6 |
DC11436 |
YLT-11
Featured
YLT-11 is a novel and specific PLK4 inhibitor with IC50 of 22 nM and Kd of 5.2 nM. |
|
DC7436 |
JAK2 Inhibitor V,Z3
Featured
Z3(NSC 42834), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. |
195371-52-9 |
DC7667 |
ZM 39923 hydrochloride
Featured
ZM 39923 is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 µM, respectively). |
1021868-92-7 |
DC5199 |
S-Ruxolitinib (INCB018424)
Featured
S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3. |
941685-37-6 |
DC40051 |
Fedratinib hydrochloride hydrate
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
1374744-69-0 |
DC40121 |
(R)-Lisofylline
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research. |
100324-81-0 |
DC40139 |
JAK-IN-5 hydrochloride
JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
|
DC40168 |
SHR0302
SHR0302 is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects. |
1445987-21-2 |
DC40459 |
FM-479
Featured
FM-479 is the negative control of FM-381 and has no activity on JAK3 or other kinases. |
2226521-64-6 |
DC40513 |
BD750
Featured
BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively. |
892686-59-8 |